U

University of Pisa | Department of Dermatology

Research site

(Unclaimed)

Location

Via Roma 67, Pisa, Pisa, Italy

Site insights

Top conditions

Top treatments

Dopamine

Rezafungin

sulphonylurea

Dapagliflozin

Linsitinib

Zimura

Troriluzole

Phthalates

OM-85

Saxagliptin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 46 total trials

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) (LIDS)

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twi...

Active, not recruiting

Thyroid Diseases

Graves Ophthalmopathy

Drug: Placebo

Drug: Linsitinib

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only

Obsessive Compulsive Disorder

Drug: Troriluzole (BHV-4157)

OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness

This study will assess the efficacy and safety of OM-85 compared to placebo in reducing the number of respiratory tract infections (RTIs) in children...

Active, not recruiting

Wheezing Lower Respiratory Illness

Respiratory Tract Infections

Drug: Placebo

Drug: OM-85

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

The goal of this clinical trial is to to evaluate the drug rezafungin in the treatment of Chronic Pulmonary Aspergillosis (CPA) in male and female pa...

Enrolling

Chronic Pulmonary Aspergillosis

Drug: Rezafungin Acetate

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of...

Active, not recruiting

Thyroid Eye Disease

Drug: Teprotumumab

Drug: Placebo